Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2026

Conditions
Recurrent Extensive Stage Small Cell Lung CarcinomaRefractory Extensive Stage Small Cell Lung Carcinoma
Interventions
DRUG

Talazoparib

Given PO

DRUG

Temozolomide

Given PO

Trial Locations (6)

32806

Orlando Health, Inc. d/b/a Orlando Health UF Health Center, Orlando

46804

Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne

67214

Cancer Center of Kansas, Wichita

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92835

St. Joseph Heritage Healthcare, Fullerton

93309

CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Translational Research in Oncology

OTHER

collaborator

Pfizer

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER